Clinical Trials Sponsored by Profil Institut für Stoffwechselforschung GmbH

Total 298 results

Profil Institut für Stoffwechselforschung GmbH

Terminated

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH

Completed

A Trial Investigating the Influence of Injection Speed and Volume on the Perception of Subcutaneous Injection Pain

Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH

Active, not recruiting

Clinical Experimental Study to Investigate Specific Features of ClampArt®

Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH

Completed

Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment

Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH

Completed

A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1

Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH

Completed

Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus (DLW)

Diabetes

Germany
Profil Institut für Stoffwechselforschung GmbH

Completed

Explorative Assessment of Biomarkers in Overweight and Obese Subjects

Prediabetes

Germany
Profil Institut für Stoffwechselforschung GmbH

Completed

Empagliflozin and Sympathetic Nerve Traffic

Type 2 Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH

Completed

A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test (DXM2)

Type 2 Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH

Withdrawn

An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms

Diabetes Type 1 | Prediabetes | Diabetes Type 2
Profil Institut für Stoffwechselforschung GmbH

Completed

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

Type 2 Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

A Trial Investigating the Accuracy and Precision of the BGStar® and iBGStar® Blood Glucose Meter in Subjects With Type 1 Diabetes

Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

Type 2 Diabetes

Germany
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy Volunteers

Diabetes

Germany
Profil Institut für Stoffwechselforschung GmbH
Pfizer

Terminated

DIATOR-Diabetes Intervention With Atorvastatin

Type 1 Diabetes

Germany
Saniona
Profil Institut für Stoffwechselforschung GmbH

Completed

Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying

Diabetes Mellitus

Germany
Biocon Limited
Profil Institut für Stoffwechselforschung GmbH

Completed

Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N

Healthy Volunteer

Germany
Spiden AG
Profil Institut für Stoffwechselforschung GmbH

Recruiting

Spiden Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)

Type 1 Diabetes | Type2diabetes

Germany
Zealand Pharma
Profil Institut für Stoffwechselforschung GmbH

Recruiting

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Safety and Tolerability

Germany
Biocon Limited
Profil Institut für Stoffwechselforschung GmbH

Completed

Comparison of the Pharmacokinetic and Pharmacodynamic Properties of Biocon's Insulin R U-500 With Humulin® R U-500 (US Reference Product) in Healthy Subjects (RHINE-4)

Healthy Volunteers

Germany
Biocon Limited
Profil Institut für Stoffwechselforschung GmbH

Completed

Comparision of Pharmacokinetics(PK) and Pharmacodynamics(PD) of Biocon Insulin R and Humulin® R

Healthy Volunteer

Germany
Biocon Limited
Profil Institut für Stoffwechselforschung GmbH

Completed

Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30

Healthy Volunteer

Germany
Medtronic Diabetes
Profil Institut für Stoffwechselforschung GmbH

Completed

New Generation Enlite Accuracy Study

Diabetes
Profil Institut für Stoffwechselforschung GmbH
European Union

Completed

Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages

Diabetes Mellitus Type 1

Germany
Profil Institut für Stoffwechselforschung GmbH
OptiScan Biomedical Corporation

Completed

Performance Study Using the OptiScanner on Healthy Diabetics

Diabetes

Germany
Dance Biopharm Inc.
Profil Institut für Stoffwechselforschung GmbH

Completed

Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Germany
TME Pharma AG
Profil Institut für Stoffwechselforschung GmbH

Completed

NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH
Emisphere Technologies, Inc.

Completed

Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes

Germany
Profil Institut für Stoffwechselforschung GmbH
Pendragon Medical AG Switzerland

Completed

Changes in Serum Electrolytes at Different Glucose Concentrations + Impact on a Non-invasive Glucose Monitoring Method

Diabetes Mellitus

Germany
Julphar Gulf Pharmaceutical Industries
Profil Institut für Stoffwechselforschung GmbH

Completed

Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal

Diabetes Mellitus

Germany
Julphar Gulf Pharmaceutical Industries
Profil Institut für Stoffwechselforschung GmbH

Completed

Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III

Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH
Novo Nordisk A/S

Completed

Metabolic Effect of Insulin Aspart and Human Insulin in Different Doses

Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH
Merck Sharp & Dohme LLC

Completed

Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

Pharmacological Action

Germany
Profil Institut für Stoffwechselforschung GmbH
Heinrich-Heine University, Duesseldorf

Completed

Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects (DXM/AMT)

Type 2 Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH
Pendragon Medical AG Switzerland

Completed

Glucose Clamp Study to Prove Hypo- and Hyperglycemic Episodes Using a Non-invasive Glucose Monitoring Device

Diabetes Mellitus

Germany
Julphar Gulf Pharmaceutical Industries
Parexel; Profil Institut für Stoffwechselforschung GmbH

Completed

Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics of Julphar Insulin R and Huminsulin® Normal

Diabetes Mellitus

Germany
Biocon Limited
Juvenile Diabetes Research Foundation; Profil Institut für Stoffwechselforschung...

Terminated

Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil

Type 1 Diabetes Mellitus (T1DM)

Germany
University of Cambridge
Medical University of Graz; Profil Institut für Stoffwechselforschung GmbH

Completed

Closing the Loop in Adults With Sub-optimally Controlled Type 1 Diabetes Under Free Living Conditions (AP@home04)

Type 1 Diabetes

United Kingdom, Austria, Germany
KeyBioscience AG
Eli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...

Terminated

A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM

Type II Diabetes Mellitus

Germany
University of Cambridge
Medical University of Graz; Cambridge University Hospitals NHS Foundation Trust and other collaborators

Completed

Short Term Closed-loop Glucose Control in Adults With Type 1 Diabetes (AP@home02)

Type 1 Diabetes

United Kingdom, Germany, Austria
Perosphere Pharmaceuticals Inc, a wholly owned...
Profil Institut für Stoffwechselforschung GmbH

Withdrawn

Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Germany
Profil Institut für Stoffwechselforschung GmbH
Icahn School of Medicine at Mount Sinai; Heart and Diabetes Center North-Rhine...

Completed

Effects of Food Advanced Glycation Endproducts on Vascular Function in Diabetes

Type 2 Diabetes Mellitus

Germany
IHF GmbH - Institut für Herzinfarktforschung

Recruiting

Post-Market Registry to Evaluate the Safety and Efficacy of the The SUPRAFLEX CRUZ™ Sirolimus Eluting Coronary Stent System in the Treatment of an Octo- and Nonagenerian All-Comer Patient Cohort With Coronary Artery Disease - the Cruz Senior Study

Coronary Disease

Germany
IHF GmbH - Institut für Herzinfarktforschung

Completed

Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes (Real-TICA)

Acute Coronary Syndrome (ACS)

Germany
IHF GmbH - Institut für Herzinfarktforschung

Not yet recruiting

BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation

Emphysema or Chronic Obstructive Pulmonary Disease

Germany
IHF GmbH - Institut für Herzinfarktforschung

Recruiting

Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes

Heart Failure

Germany
AvenCell Europe GmbH
PHARMALOG Institut für klinische Forschung GmbH

Recruiting

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

Prostate Cancer

Germany
AvenCell Europe GmbH
PHARMALOG Institut für klinische Forschung GmbH

Recruiting

Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Acute Myeloid Leukemia (AML)

Germany
Institut fur Diabetes Karlsburg GmbH
Beurer GmbH

Completed

System Accuracy of BGM GL60

Diabetes Mellitus

Germany

Clinical Trials Sponsored by Profil Institut für Stoffwechselforschung GmbH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations